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ABSTRACT
INTRODUCTION: Liver diseases (hepatitis, steatosis, non-alcoholic fatty liver disease, cirrhosis and he-
patocellular carcinoma) are among the most common causes of disability and death worldwide. An accumu-
lating body of evidence has established a relationship between the intake of polyphenol-rich foods and bev-
erages and the lower incidence of liver diseases. Flavonoids are important ingredients in human diet.
AIM: The aim or the present review article was to summarize the current knowledge about the effects of fla-
vonoids on liver health and the mechanisms involved.
MATERIALS AND METHODS: Literature in Pubmed, Google Scholar and ScienceDirect has been stud-
ied and analyzed.
RESULTS: Flavonoids protect the liver from viral, toxic, drug-induced and obesity-associated liver dam-
age, but the data are almost exclusively derived from animal studies. However, the number of clinical trials 
is insufficient and additional human studies are needed to confirm their effect in clinical practice.
CONCLUSION: Analysis of the literature data from scientific databases showed promising hepatoprotec-
tive effects of flavonoids proved predominantly in experimental animal studies.
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INTRODUCTION
 Liver diseases (hepatitis, steatosis, non-alco-
holic fatty liver disease—NAFLD, cirrhosis and he-
patocellular carcinoma—HCC) are among the most 
common causes of disability and death worldwide. 
It is estimated that 2 million deaths per year are due 
to complications of these conditions (1). The etiolo-
gy of liver diseases includes alcohol abuse, viral in-
fections, medications, rising incidence of metabolic 
syndrome and autoimmunity (2–5). Inflammation, 
oxidative stress and abnormal immune response play 
central role in the pathogenesis of these diseases (6). 
These scientific data serve as valuable tools for seek-
ing new therapeutic options, including phytothera-
peutic ones.
Polyphenols (PPs) are natural compounds 
ubiquitously presented in fruits, vegetables, tea, cof-
fee and other beverages. They contribute to the bit-
ter or astringent taste of foods. PPs protect plants 
against aggressive factors such as ultraviolet radia-
tion and infectious agents as well as attract pollina-
tors (7). Generally, PPs are divided into two groups: 
flavonoids and non-flavonoids. The main flavonoids 
include flavones, flavonols, flavan-3-ols (flavanols), 
flavanones, isoflavones and anthocyanins (Fig.1). It 
is estimated that the mean daily flavonoid intake in 
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MATERIALS AND METHODS
Databases such as PubMed, ScienceDirect and 




The most studied flavones include apigenin, 
luteolin, and tangeretin. A number of pre-clinical 
studies have identified the role of these compounds 
in the prevention and treatment of liver diseases (10–
17). Most of the experiments are conducted with the 
use of a hepatotoxic agent or with a specific experi-
mental model associated with liver damage.
European adults is as high as 428 ± 49 mg (8). In the 
last decade flavonoids have attracted scientific inter-
est due to their numerous health benefits. An accu-
mulating body of evidence has established a relation-
ship between the intake of polyphenol-rich (includ-
ing flavonoid-rich) foods and beverages and the low-
er incidence of liver diseases (9).
AIM
The current contribution is focused on the ef-
fects of different classes of flavonoids on liver health 
and the mechanisms involved. 
Fig. 1. Flavonoids—classification
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The literature review shows that apigenin sup-
presses hepatic inflammation and oxidative damage, 
decreases the fibrotic tissue in the liver, alleviates liv-
er steatosis, and prevents hepatocyte death. More-
over, it prevents liver damage by stimulating the cel-
lular antioxidant defense system (free radical scav-
enging; activation of the antioxidant enzymes—su-
peroxide dismutase, glutathione peroxidase, gluta-
thione reductase, glutathione S-transferase) (10–12). 
It also suppresses of the pro-inflammatory pathways 
(non-canonical NF-κB pathway) (10), modulates sir-
tuin 1 activity (involved in oxidative stress and in-
flammatory response) (12), and alleviates hepato-
cyte autophagy and apoptosis (13,14). Nonetheless, 
one animal study revealed a dose-dependent hepa-
totoxic effect of apigenin through oxidative damage 
when injected intraperitoneally (15). Currently, there 
are no documented clinical trials with apigenin used 
as a phytotherapeutic agent. Further human studies 
are needed to clarify the effects of this flavone on the 
liver.
 Luteolin is found in broccoli, pepper, thyme, 
and celery (16). Studies suggest that this flavone can 
suppress hepatic fibrosis through induction of apop-
tosis of the fibrotic tissue forming hepatic stellate 
cells and improve NAFLD by regulating lipid metab-
olism, suppressing the inflammation, and enhancing 
the antioxidant defense system of hepatocytes (18-22, 
24). There are no clinical trials assessing the hepatic 
effects of luteolin.
In terms of liver effects, tangeretin has been 
mostly studied for its potential antitumor activity 
(against HCC). In vitro and in vivo studies have re-
vealed that its potential anticancer effects are due to 
improved intercellular connections between hepato-
cytes, suppressed proliferation and migration of ma-
lignant cells, tumor cell cycle arrest and induction of 
apoptosis of the cancer cells (25–27). In another mod-
el, tangeretin counteracted the hepatotoxic effects of 
the chemotherapeutic agent cisplatin by suppressing 
the activity of pro-inflammatory cytokines, up-reg-
ulation of anti-inflammatory cytokines and stimu-
lating the oxidative stress-combating enzymes (26).
Flavonols
Quercetin is the most broadly investigated 
flavonol—а flavonoid with а ketone group. It is pres-
ent in vegetables (onion, kale, tomato), fruits (apple, 
grapes, berries), and beverages (tea, red wine) (17).
Both in vivo and in vitro studies underline the 
role of quercetin in preventing liver damage caused 
by obesity (28,29), drugs (chemotherapeutic agents) 
(30) and toxins (alcohol) (31). Quercetin protects the 
liver by preventing VLDL processing and hepatic 
storage, ameliorating liver inflammation and oxida-
tive stress as well as by stimulating ethanol-metabo-
lizing enzyme systems (19–23).
Quercetin possesses pro-oxidant properties, 
which determine its anti-cancer activity. Intracellu-
larly, this flavonol is converted to o-quinone, which 
exerts dose-dependent cytotoxic effects. However, lo-
cal enzymes, such as nicotinamide adenine dinucleo-
tide phosphate oxidase (NADPH oxidase) or NAD(P)
H:quinone reductase (DT-diaphorase), restore the 
cellular level of quercetin, which could be a mech-
anism of preventing intact cell damage. Moreover, 
this flavonoid induces apoptosis and leads to death 
of malignant cells in HCC, as documented in vitro 
(32) and in vivo (33). Additionally, quercetin acts as 
a “sensitizer” to boost the efficacy of other chemo-
therapeutic approaches investigated for HCC thera-
py (33).
Flavan-3-ols (Flavanols)
These chemical compounds are found in high 
quantities in green tea (Camellia sinensis), cocoa, and 
banana. The main flavanols include catechin, epicat-
echin, epigallocatechin, and epigallocatechin gallate 
(EGCG). The literature review highlights the role of 
these flavonoids (especially EGCG) in the prevention 
and treatment of NAFLD and HCC. According to 
the results from preclinical studies, flavan-3-ols ex-
ert beneficial effects in NAFLD due to their antiox-
idant, anti-inflammatory and energy metabolism-
regulating activities. The intimate mechanisms of 
these protective effects include: weight loss, stimu-
lation of LDL-cholesterol clearance and suppressed 
triglyceride synthesis, activation of hepatic adenos-
ine monophosphate (AMP)-activated protein ki-
nase (central regulator of the energy metabolism), 
improved mitochondrial respiration, enhanced in-
sulin sensitivity and reduced expression of fibro-
sis-stimulating molecules in the liver (transform-
ing growth factor-beta—TGF-β and collagen I-α1) 
(34). Although results from clinical trials confirmed 
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these benefits, the study samples are small, the ad-
ministrated doses or used substances are different, 
which could explain some of the discrepancies ob-
served. For instance, pure EGCG administration did 
not produce the same protective effect as mixed cat-
echins in green tea extract (35).
The HCC preventive effects of green tea cate-
chins are broadly studied and documented.  A num-
ber of in vitro studies reported that they induced 
apoptosis of cancer cells and reduced the expression 
of growth factors (insulin-like growth factor 1/2, 
platelet-derived growth factor, epidermal growth fac-
tor) and their receptors (36). In vivo preclinical stud-
ies (animals with experimental models of liver can-
cer) confirmed these effects. Furthermore, most of 
them were described in metabolic syndrome mod-
els of liver carcinogenesis (36). Although clinical tri-
als with green tea catechins found a relation between 
higher polyphenol intake and reduced risk of certain 
benign or malignant tumors (colorectal adenomas, 
colorectal carcinoma, prostate carcinoma, leucopla-
kia), the effects on the risk of HCC were conflicting 
and inconclusive. Indeed, a review reported no de-
crease in the incidence of HCC (37). The authors sug-
gested the design of the studies presumably contrib-
uted to the observed results. 
A potential drawback of catechins might be 
their ability to induce hepatotoxicity. Review of the 
published data shows that green tea catechins in-
duce several xenobiotic-metabolizing cytochrome 
(CYP) isoforms (CYP1A2, CYP2D6, CYP2C9, and 
CYP3A4) and produce cytotoxic metabolites (acting 
as pro-oxidants). Interestingly, most of the report-
ed cases of liver toxicity involve women (38). These 
data should be taken into account when conducting 
a clinical trial.
Flavanones
Citrus fruits (orange, lemon, lime) are rich 
sources of flavanones (naringenin, hesperidin). It is 
estimated that flavanone content may vary between 
180 and 740 mg/L according to the citrus species (39).
Naringenin has well-documented effects on 
the liver health. It has been shown to protect the liv-
er from toxic (alcohol, carbon tetrachloride, heavy 
metals), pro-oxidant or viral damage as well as from 
malignant transformation (40). Alcohol is known 
to induce liver damage and fibrosis through oxida-
tive stress, acetaldehyde accumulation, alternation in 
CYP2E1 activity and lipid accumulation. Naringenin 
prevents these damaging effects through induction 
of the alcohol-metabolizing enzyme alcohol dehy-
drogenase (thus decreasing acetaldehyde), suppres-
sion of free radical formation and scavenging. Car-
bon tetrachloride (CCl4) is a hepatotoxic agent, used 
in experimental medicine to induce liver fibrosis and 
cirrhosis. Naringenin prevents CCl4-induced fibrot-
ic changes in the liver by suppressing its metabo-
lism to toxic CCl3OO
. radical, preventing the activity 
of apoptotic pathways, down-regulating the inflam-
matory cytokines (interleukin-1/6 and tumor necro-
sis factor-α) and enzymes (cyclooxygenase-2 and in-
ducible nitric oxide synthase), preventing the activ-
ity of the pro-fibrotic factor TGF-β. As a strong an-
tioxidant, it prevents oxidative stress-mediated liv-
er changes (including from heavy metals) through 
stimulating the antioxidant defense system in the 
body (superoxide dismutase, glutathione, glutathione 
peroxidase, catalase). Furthermore, this flavanone is 
shown to possess antiviral properties through inhib-
iting non-structural proteins (such as NS2, NS5A) 
of the hepatitis C virus.  The anticancer activity is 
thought to be due to its antioxidant effects, inhibition 
of signaling pathways (MAP kinase, PI3/AKT, NF-
κB) activation of p53 (tumor suppressоr gene), G0/
G1 phase arrest, induction of apoptosis (due to cyto-
chrome c release) and suppression of the angiogen-
esis (mediated by vascular endothelial growth fac-
tor) (41). Similar benefits (without antiviral activity) 
are documented for the other flavanone—hesperidin 
(41,42).  
Isoflavones
Genistein, daidzein, puerarin and formonone-
tin belong to the group of isoflavone-type flavonoids. 
They are highly present in legumes (soybeans) and 
red clover (Trifolium pratense) (43). In rodent mod-
els of obesity and metabolic syndrome, high intake 
of these phenols was inversely associated with the 
development of liver disease (alcoholic, non-alcohol-
ic) and its progression. In addition, knockout mice 
models of dyslipidemia were improved with high 
consumption of genistein and formononetin. Unex-
pectedly, the last was potent enough to induce liver 
steatosis in one of the studies although it alleviated 
liver inflammation in animals fed a cholesterol-rich 
diet. It is supposed that isoflavones inhibit aldose re-
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ductase activity and polyol pathway (thus, the pro-
duction of fructose in the liver), activate peroxisome 
proliferator-activated receptor-alpha (PPAR-α), alle-
viate CYP21E-mediated oxidative stress and endo-
toxin-mediated NF-κB activation (44). 
The number of clinical studies with isoflavones 
is limited. One study among 6786 Chinese adults 
revealed that isoflavonoid intake is associated with 
lower risk of NAFLD, hyperlipidemia, and arterial 
hypertension (45). 
Although isoflavones possess phytoestrogenic 
activity, they do not tend to increase the risk of es-
trogen-dependent malignant conditions (such as en-
dometrial, breast and liver cancer) in females, when 
consumed in a dietary level (<100 mg/day) (46,47). 
Moreover, these compounds elicit anti-estrogenic ac-
tivity. Therefore, some authors report improvement 
in hyperestrogenic states with isoflavone consump-
tion (48).
Anthocyanins
Anthocyanins (ACNs) (cyanidin, delphinidin, 
malvidin, peonidin, petunidin) are responsible for 
the blue to purple color of fruits, vegetables and flow-
ers. The average daily intake ranges between 180 mg 
and 215 mg. Although they have low bioavailability, 
regular dietary intake has shown to possess positive 
impact on liver lipid metabolism and lowers the risk 
of NAFLD (49). In vitro studies on HepG2 hepato-
ma cells have revealed that both cyanidin and total 
ACN extract promote lipolysis and inhibit lipogen-
esis, thus reduce the lipid accumulation in the liver. 
Additionally, ACNs stimulate AMPK-pathway and 
PPAR-mediated lipid metabolism. In vivo studies 
with healthy, obese, metabolic syndrome or steato-
hepatitis rats/mice have identified similar outcomes. 
The available evidence supports the in vitro effects 
of ACNs with effect on the lipid storage in the liv-
er. In those experiments, ACNs were associated with 
weight loss, improved insulin resistance and reduced 
severity of steatohepatitis. 
Anthocyanins belong to the strongest antioxi-
dants and protect the liver from oxidative damage. 
Such effects are documented in vivo in studies with 
sweet potato (50,51), bilberry (52) and chokeberry 
Described Effect In Vitro Studies Animal Studies Human Studies
Anti-inflammatory Yue et al.(10)
Yue et al. (10); Wang et al. (11); Zhang et al. 
(24); Omar et al. (26); Yang et al. (29); Chen 
et al. (31); Popović et al. (52)
Guo et al. (58)
Antioxidant
Zhai et al. (12);  
Kondeva-Burdina et al. 
(56)
Wang et al. (11); Zhai et al. (12); Wang et 
al. (23); Zhang et al. (24); Omar et al. (26); 
Yang et al. (29);  Chen et al. (31); Choi et 
al. (50); Jiang et al. (51); Popović et al. (52); 
Valcheva-Kuzmanova et al. (53): Valcheva-
Kuzmanova et al. (54); Valcheva-Kuzmano-
va et al. (55)
Guo et al. (58)
Antifibrotic Ji et al. (13); Li et al. (18) Ji et al (13); Li et al. (18); Popović et al. (52)
Antihyperlipidemic Zhu et al. (28);  Yang et al. (29)
Kwon et al. (19); Liu et al. (20); Yin et al. 
(22);  Omar et al. (26); Zhu et al. (28); Yang 
et al. (29)
Chang et al. (57)
Anti-apoptotic Tsaroucha et al. (14) Tsaroucha et al. (14); Omar et al. (26) Guo et al. (58)
Anti-cancer
Zheng et al. (25);  
Chaumontet et al. (27); 
Zhou et al. (32);  
Zou et al. (33);  
Banjerdpongchai et al. 
(42)
Insulin-sensitizing Zhang et al. (59)
Table 1. In vitro and in vivo investigations of the effects of flavonoids on the liver
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(52–56). For instance, Aronia melanocarpa (choke-
berry) juice (rich in anthocyanins) administered 
both as pretreatment or post-treatment in a mod-
el of CCL4-induced hepatotoxicity, has shown a very 
good hepatoprotective effect accompanied by antiox-
idant activity (53, 54). Moreover, the protective effect 
of Aronia-derived anthocyanins on liver lipid peroxi-
dation was comparable to that of quercetin (55).  The 
protective effect of anthocyanin-rich Aronia melano-
carpa fruit juice has been also described in a model of 
tert-butyl hydroperoxide-induced hepatotoxicity and 
oxidative stress on isolated rat hepatocytes (56).
However, as with other flavonoids, there are 
few clinical studies conducted with ACNs. In one of 
them, H. sabdariffa extract improved liver steatosis 
after 3 months (57). Another study showed that an-
thocyanin-rich bayberry (myrica) juice improved the 
oxidative stress, inflammation and apoptosis in indi-
viduals with NAFLD (58). Zhang et al. assessed the 
liver benefits of purified bilberry and black currant 
ACN extracts and found that they improve insulin 
resistance, markers of hepatic injury and the clinical 
evolution of NAFLD (59).
Table 1 sums up the in vitro and in vivo studies 
investigating the effects of flavonoids on liver health:
In summary, many studies have been concen-
trated on the investigation of the effects of flavonoids 
on the liver. Based on the available scientific data fla-
vonoids possess multiple mechanisms responsible for 
their documented hepatoprotective effects such as 
exerting anti-inflammatory, antioxidant, antiapop-
totic, antihyperlipidemic, anticancer, antiviral, and 
antifibrotic effect. However, still the number of clini-
cal studies is limited, therefore, more and more pre-
cise clinical studies are needed to explore their effects 
in real patients with liver diseases.
Fig. 2. Mechanisms of hepatoprotective effects of flavonoids
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Fig. 2 summarizes the mechanisms involved in 
the hepatoprotective effects of the flavonoids.
CONCLUSION
Flavonoids are important ingredients in human 
diet. Analysis of the literature data from scientific 
databases shows promising hepatoprotective effects 
of flavonoids in experimental settings. However, the 
number of clinical trials is insufficient and addition-
al human studies are needed to confirm their effect 
in clinical practice.
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